Xenaderm

The unapproved bed sore drug Xenaderm, which was marketed to nursing homes as "Medicaid reimbursed," is the source of a settlement that could reach $48 million for Healthpoint Ltd. and DFB Pharmaceuticals.

McKnight's Daily Update

McKnight's Market Buzz

McKnight's Market Focus

McKnight's Spotlight On

McKnight's Weekly Roundup

I would like to receive relevant information via email from McKnight's Long-Term Care / Senior Living.

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions